DermTech, Inc. (DMTK)

NASDAQ: DMTK · IEX Real-Time Price · USD
5.68
+0.16 (2.90%)
Feb 2, 2023, 10:32 AM EST - Market open
2.9%
Market Cap 172.22M
Revenue (ttm) 14.69M
Net Income (ttm) -114.51M
Shares Out 30.21M
EPS (ttm) -3.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 177,084
Open 5.70
Previous Close 5.52
Day's Range 5.55 - 5.89
52-Week Range 1.55 - 16.33
Beta 1.76
Analysts Buy
Price Target 7.48 (+31.69%)
Earnings Date Mar 7, 2023

About DMTK

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflam... [Read more]

Sector Healthcare
CEO Dr. John D. Dobak M.D.
Employees 255
Stock Exchange NASDAQ
Ticker Symbol DMTK
Full Company Profile

Financial Performance

In 2021, DermTech's revenue was $11.84 million, an increase of 101.16% compared to the previous year's $5.89 million. Losses were -$78.34 million, 114.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for DMTK stock is "Buy." The 12-month stock price forecast is $7.48, which is an increase of 31.69% from the latest price.

Price Target
$7.48
(31.69% upside)
Analyst Consensus: Buy
Stock Forecasts

News

DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced th...

6 days ago - Business Wire

DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced fa...

1 week ago - Business Wire

DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced th...

3 weeks ago - Business Wire

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced fa...

1 month ago - Business Wire

DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced th...

1 month ago - Business Wire

DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test

LA JOLLA, Calif. & PHOENIX--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announce...

2 months ago - Business Wire

DermTech, Inc. (DMTK) Reports Q3 Loss, Misses Revenue Estimates

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 3.03% and 26.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

DermTech Reports Third-Quarter 2022 Financial Results

LA JOLLA, Calif.

3 months ago - Business Wire

DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA Congress

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its ...

4 months ago - Business Wire

DermTech Presents on Technological Advances and the Value of Decentralization at Outsourcing in Clinical Trials Southern California

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its ...

4 months ago - Business Wire

DermTech, Inc. (DMTK) Reports Q2 Loss, Lags Revenue Estimates

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 2.94% and 14.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

DermTech Reports Second-Quarter 2022 Financial Results; Company Updates Full-Year 2022 Outlook

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its s...

6 months ago - Business Wire

Earnings Preview: DermTech, Inc. (DMTK) Q2 Earnings Expected to Decline

DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

DermTech Appoints Chief Compliance Officer and SVP of Research and Development

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, has appointed two ne...

6 months ago - Business Wire

DermTech Announces Release Date for Second-Quarter 2022 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conferen...

6 months ago - Business Wire

DermTech Appoints Two New Board Members

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the ...

7 months ago - Business Wire

DermTech Joins PeDRA Corporate Council, Supporting Efforts to Address Pediatric Skin Diseases

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its ...

7 months ago - Business Wire

DermTech to Present on Genomic Innovation in Dermatology at AHIP 2022

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that...

8 months ago - Business Wire

DermTech to Present at the William Blair Growth Stock Conference

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that...

8 months ago - Business Wire

DermTech Sponsors The Sun Bus to Bring Free Skin Cancer Screenings to More Than 50 Locations Across the U.S.

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that...

9 months ago - Business Wire

DermTech Presents New Research Differentiating Atopic Dermatitis and Psoriasis at the Society for Investigative Dermatology's Annual Meeting

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its ...

9 months ago - Business Wire

DermTech Reinforces Longstanding Mission to Help Reduce Melanoma Deaths, Aligning with the Biden Administration's Renewed ‘Cancer Moonshot' Program

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its ...

9 months ago - Business Wire

DermTech Kicks Off Second Annual #Stickit2Melanoma Campaign, Raising Awareness for Melanoma and the Importance of Skin Exams

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the ...

9 months ago - Business Wire

DermTech, Inc. (DMTK) Reports Q1 Loss, Misses Revenue Estimates

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -18.82% and 1.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research